Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies

Authors not listed

Atria Research and Global Health Institute (ARGHI) · 2025

Abstract

This is a multi-cohort, open-label, adaptive trial designed to evaluate the safety, tolerability, and biological effects of dietary supplements and other aging-targeted therapies. Cohort 1 is a single-arm, open-label, intrapatient dose-escalation study evaluating the effects of escalating doses of spermidine in 10 participants. Patients will have baseline blood drawn and subsequently start daily administration of spermidine. They will receive capsules for three consecutive 28-day courses with escalating doses of 40mg, 120mg, and 400mg. Subsequent cohorts will evaluate additional agents.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-13 MST

Cite this

APA
Anonymous. (2025). Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies. <em>Atria Research and Global Health Institute (ARGHI)</em>. https://clinicaltrials.gov/study/NCT07202403
Vancouver
Anonymous. Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies. Atria Research and Global Health Institute (ARGHI). 2025.
BibTeX
@misc{anon2025Iterat, title = {Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies}, author = {Anonymous}, journal = {Atria Research and Global Health Institute (ARGHI)}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings